Bio-Path Holdings (BPTH) Recent Earnings

Bio-Path Holdings (BPTH) reported a Quarter September 2025 loss of $0.11 per share on revenue of $0.0 million..

Bio-Path Holdings Inc is a development stage company. The Company with its lead cancer drug candidate, Liposomal Grb-2, is currently in clinical trials.